Novo Nordisk A/S
NONOF
$136.48
-$1.77-1.28%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.82B | 9.52B | 9.51B | 8.58B | 7.93B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.82B | 9.52B | 9.51B | 8.58B | 7.93B |
| Cost of Revenue | 1.48B | 1.44B | 1.45B | 1.42B | 1.15B |
| Gross Profit | 8.34B | 8.07B | 8.06B | 7.16B | 6.79B |
| SG&A Expenses | 2.32B | 2.10B | 2.69B | 2.06B | 2.25B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -58.44M | 82.70M | -433.10K | -14.31M | 2.19M |
| Total Operating Expenses | 5.26B | 4.88B | 5.44B | 4.65B | 4.44B |
| Operating Income | 4.56B | 4.64B | 4.07B | 3.93B | 3.49B |
| Income Before Tax | 3.66B | 4.65B | 3.99B | 4.10B | 3.54B |
| Income Tax Expenses | 762.14M | 948.04M | 816.66M | 815.64M | 705.13M |
| Earnings from Continuing Operations | 2.89B | 3.70B | 3.17B | 3.28B | 2.84B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.89B | 3.70B | 3.17B | 3.28B | 2.84B |
| EBIT | 4.56B | 4.64B | 4.07B | 3.93B | 3.49B |
| EBITDA | 5.02B | 5.06B | 4.28B | 4.30B | 3.81B |
| EPS Basic | 0.65 | 0.83 | 0.71 | 0.73 | 0.63 |
| Normalized Basic EPS | 0.63 | 0.65 | 0.59 | 0.57 | 0.49 |
| EPS Diluted | 0.65 | 0.83 | 0.71 | 0.73 | 0.63 |
| Normalized Diluted EPS | 0.63 | 0.65 | 0.58 | 0.57 | 0.49 |
| Average Basic Shares Outstanding | 4.46B | 4.46B | 4.46B | 4.48B | 4.49B |
| Average Diluted Shares Outstanding | 4.47B | 4.47B | 4.48B | 4.49B | 4.50B |
| Dividend Per Share | 0.51 | -- | 0.92 | 0.00 | 0.44 |
| Payout Ratio | 0.00% | 112.40% | 0.00% | 59.75% | 0.00% |
